Bayer AG
Analysis Result: 3 out of 5 MUMAKS
Rating
This analysis assesses Bayer AG under the UMBRELLA strategy using the MUMAK method.
The valuation is conducted across five decision-making phases: Geopolitics, Industry, Fundamentals, Market Sentiment, and Technical Analysis.
The goal is not to predict the future precisely. The goal is orientation. We contextualize facts, demonstrate causal relationships, and structure a comprehensible decision logic.
We explain – you decide.
Geopolitics
Classification
The current geopolitical environment remains broadly supportive for global pharmaceutical and agricultural companies.
Key Takeaway
- The growing importance of food security, healthcare, and resilient supply chains supports long-term demand for Bayer AG’s products.
- The war in Ukraine, geopolitical tensions between the US and China, and the rising need for productive and sustainable agriculture are increasing the strategic importance of modern seed and crop protection technologies.
- The US remains Bayer’s most important single market, in both the pharma and agriculture segments. This gives the company exposure to an attractive market environment, but also makes it more vulnerable to political and regulatory changes and litigation.
- At the same time, regulatory and political risks are increasing. In particular, crop protection products, genetic technologies, and sustainability requirements are increasingly in the spotlight of governments and authorities in Europe, North America, and other key markets.
- Bayer is strategically positioned as one of the world’s leading life-science groups, with a strong presence in the US, Europe, and key international agricultural and pharmaceutical markets. This leaves the company well placed to benefit from long-term trends in health and nutrition.
MUMAK.me Assessment Phase 1: Positive = 1 MUMAK
Bayer AG
Geopolitics Rating: positive
Industry
Assessment
The pharmaceutical and agricultural industries continue to benefit from structural demand growth, high barriers to entry, and long-term global megatrends such as population growth, ageing societies, and food security.
Valuation comparison: Bayer vs. sector peers
| Metric | Bayer | Industry Average* | Rating |
|---|---|---|---|
| P/E Ratio | N/M (negative earnings) | approx. 16–22x | Discount |
| EV/EBITDA | approx. 5–6x | approx. 10–14x | Significant discount |
| Gross margin | approx. 57% | approx. 65–75% | Discount |
| Revenue Growth | approx. -2% to +1% | approx. 4–8% | Discount |
*Based on Novartis, Roche, Sanofi, Merck KGaA, Corteva, and other major pharmaceutical and agricultural companies.
Key Takeaway
- Rising demand for pharmaceuticals, advanced seed solutions, and efficient agriculture supports the sector’s long-term development.
- Trends such as precision agriculture, sustainable yield improvements, and innovation in pharmaceutical research provide planning certainty over multiple years.
- In particular, the agriculture business is among the world’s leading providers of seeds and crop protection products, while the pharma business benefits from a strong position in selected therapeutic areas.
- At the same time, the sector remains heavily regulated; pricing pressure in healthcare, stricter environmental requirements, and patent cycles remain key drivers of long-term profitability.
MUMAK.me Phase 2 Rating: Neutral = 0 MUMAK
Bayer AG
Industry Rating: neutral
Fundamentals
Assessment
Bayer AG’s fundamentals present a mixed picture. While profitability is improving significantly and operational progress is becoming visible, high leverage, legal risks, and weak cash flow development continue to weigh on the company.
Outlook 2026
| Key Figure | FY 2026e |
|---|---|
| Revenue | ~ EUR 45.5 billion |
| EBITDA | ~ EUR 9.65 billion |
| Free Operating Cash Flow | ~ EUR -1.5/-2.5 billion (including ~ EUR 5 billion for litigation payouts) |
| Group net debt | ~ EUR 32–33 billion (incl. litigation payouts) |
| Forward P/E (2026e) | ~ 15x |
Financial Metrics
| Key Figure | FY 2025 |
|---|---|
| Revenue FY2025 | EUR 45.8 billion (-2% vs. 2024) |
| EBITDA FY2025 | EUR 8.87 billion (+33.9% vs. 2024) |
| FOCF FY2025 | EUR 2.1 billion (-32.9% vs. 2024) |
| Revenue 2026e | ~ EUR 45.5 billion |
| EBITDA 2026e | ~ EUR 9.65 billion |
| FOCF 2026e | ~ EUR -1.5/-2.5 billion |
Bayer AG – Financial overview. Source: Bayer AG annual financial statements 2025, Bayer makes a solid start to the year and confirms currency-adjusted group guidance for 2026, MarketScreener valuation data, accessed in June 2026.
MUMAK.me rating Phase 3: Neutral = 0 MUMAK
Bayer AG
Fundamentals rating: neutral
News, Analysts, and Market Sentiment
Assessment
Market sentiment toward Bayer AG has improved recently, but remains cautious due to glyphosate litigation, high leverage, and the expected negative free cash flow for 2026. Sentiment is supported by operational improvements, progress in restructuring, and positive analyst assessments.
Key Takeaway
- After the first quarter, Bayer AG reaffirmed its full-year outlook. In Q1, revenue of €13.4 billion was generated, while EBITDA before special items rose 9% to €4.45 billion. Group earnings improved to €2.76 billion.
- Analysts remain predominantly positive and see price targets above the current share price.
Analyst Consensus
| Average Recommendation | OUTPERFORM |
| Number of Analysts | 19 |
| Average Price Target | ~ EUR 49.50 |
| Upside to Average Target | approx. +37% |
| Upper Target | EUR 60.00 |
| Lower Target | EUR 30.00 |
Source: MarketScreener, retrieved in June 2026.
Interesting Fact
In late June or early July, the US Supreme Court is expected to decide whether consumers can claim missing warning labels on glyphosate products even though they have been classified as safe by the US Environmental Protection Agency. If the case is dismissed, remaining concerns about litigation for Bayer AG would be eliminated.
MUMAK.me Evaluation Phase 4: Positive = 1 MUMAK
Bayer AG
Market Sentiment Rating: positive
Technical Analysis
Assessment
The technical structure has improved significantly over the past twelve months. After the sharp rise from around EUR 22 to nearly EUR 50 in early 2026, the stock has been in a consolidation phase for several months. The pullback from the yearly high has so far been contained above an important support zone. At the same time, an upward-sloping medium-term trendline remains in place and was successfully defended recently.
Key Takeaway
- The long-term uptrend since summer 2025 remains intact despite the consolidation.
- A support level has been successfully defended several times.
- The stock is currently working on stabilizing within the trading range.
RSI (14)
Neutral to slightly positive
- RSI currently: approx. 51
- No overbought or oversold condition
- Recovery from the lows of recent weeks
Interpretation: Neutral with a slight upward bias.
MACD (12/26/9)
Slightly positive
- The MACD is in positive territory
- It has turned upward after the weak phase
- Early stage of a possible trend continuation
Interpretation: First technical buy signal.
Bollinger Bands (20)
Neutral to slightly bullish
- Price is trading above the lower Bollinger Band
- Return to the middle of the band achieved
- Bands are beginning to narrow slightly
Interpretation: Positive stabilization signal after the previous weak phase.
Despite positive tendencies, still cautious.
MUMAK.me Assessment Phase 5: Positive = 1 MUMAK
Bayer AG
Technical Analysis Rating: positive
Summary
The analysis shows an overall stable positive picture with an attractive long-term strategic positioning.
→ Geopolitics → Industry → Fundamental Data → Market Sentiment → Chart Analysis
Bayer remains in a challenging transformation phase. While the structurally attractive end markets of health and agriculture and the company’s strong market position offer long-term potential, glyphosate proceedings, high leverage, and regulatory challenges remain key risk factors. The decisive factors for a re-rating of the stock will be operational performance, cash flow generation, and progress in reducing legal uncertainties.
Rating According to the MUMAK Method
| Category | Rating |
|---|---|
| Geopolitics | Positive |
| Industry | Neutral |
| Fundamentals | Neutral |
| News & Sentiment | Positive |
| Technical Analysis | Positive |
